Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 4 (2007), Issue 6 (June)

  1. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
    Lancet Oncol, 8(6): 475-87. [Abstract] [Full-text]
  2. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Cancer Res, 67(11): 5498-504. [Abstract] [Full-text]
  3. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
    Cancer Res, 67(11): 5434-42. [Abstract] [Full-text]
  4. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.
    Cancer Res, 67(11): 5318-27. [Abstract] [Full-text]
  5. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
    Cancer Res, 67(11): 5221-30. [Abstract] [Full-text]
  6. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
    Cancer Res, 67(11): 5117-25. [Abstract] [Full-text]
  7. Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject.
    Stat Appl Genet Mol Biol, 6: Article14. [Abstract] [Full-text]
  8. Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs.
    Int J Radiat Oncol Biol Phys, 68(3): 903-11. [Abstract] [Full-text]
  9. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes.
    Int J Radiat Oncol Biol Phys, 68(3): 898-902. [Abstract] [Full-text]
  10. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 892-7. [Abstract] [Full-text]
  11. Intensity-modulated radiotherapy using implanted fiducial markers with daily portal imaging: assessment of prostate organ motion.
    Int J Radiat Oncol Biol Phys, 68(3): 912-9. [Abstract] [Full-text]
  12. What dose of external-beam radiation is high enough for prostate cancer?
    Int J Radiat Oncol Biol Phys, 68(3): 682-9. [Abstract] [Full-text]
  13. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
    Int J Radiat Oncol Biol Phys, 68(3): 699-706. [Abstract] [Full-text]
  14. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 690-8. [Abstract] [Full-text]
  15. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
    J Cell Physiol, 212(2): 298-306. [Abstract] [Full-text]
  16. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study.
    J Gen Intern Med, 22(7): 901-7. [Abstract] [Full-text]
  17. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.
    Future Oncol, 3(3): 329-41. [Abstract] [Full-text]
  18. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function.
    J Clin Invest, 117(6): 1647-57. [Abstract] [Full-text]
  19. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.
    Nat Clin Pract Urol, 4(6): 321-32. [Abstract] [Full-text]
  20. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Am J Clin Oncol, 30(3): 234-8. [Abstract] [Full-text]
  21. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.
    Am J Clin Oncol, 30(3): 228-33. [Abstract] [Full-text]
  22. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma.
    J Natl Cancer Inst, 99(11): 868-80. [Abstract] [Full-text]
  23. Modulating paclitaxel bioavailability for targeting prostate cancer.
    Bioorg Med Chem, 15(14): 4973-84. [Abstract] [Full-text]
  24. NMR-based metabolomics approach to target biomarkers for human prostate cancer.
    Expert Rev Proteomics, 4(3): 389-400. [Abstract] [Full-text]
  25. Prostate cancer mortality predictions for Ireland up to 2015.
    Eur J Cancer Prev, 16(4): 328-33. [Abstract] [Full-text]
  26. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
    J Clin Oncol, 25(17): 2420-5. [Abstract] [Full-text]
  27. Highly efficient cationic hydroxyethylated cholesterol-based nanoparticle-mediated gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells.
    J Control Release, 120(1): 122-30. [Abstract] [Full-text]
  28. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Cancer, 109(12): 2432-8. [Abstract] [Full-text]
  29. The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S.
    Cancer, 109(12): 2445-53. [Abstract] [Full-text]
  30. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase.
    Cancer Lett, 253(1): 124-30. [Abstract] [Full-text]
  31. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004.
    Am J Epidemiol, 166(1): 71-8. [Abstract] [Full-text]
  32. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
    Cancer Chemother Pharmacol, 60(3): 341-9. [Abstract] [Full-text]
  33. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha.
    Biochim Biophys Acta, 1771(7): 883-92. [Abstract] [Full-text]
  34. Ejaculatory disorders may affect screening for prostate cancer.
    J Urol, 178(1): 232-7; discussion 237-8. [Abstract] [Full-text]
  35. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
    J Urol, 178(1): 308-13. [Abstract] [Full-text]
  36. Under diagnosis and over diagnosis of prostate cancer.
    J Urol, 178(1): 88-92. [Abstract] [Full-text]
  37. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.
    J Urol, 178(1): 120-4. [Abstract] [Full-text]
  38. Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines.
    J Urol, 178(1): 82-7; discussion 87. [Abstract] [Full-text]
  39. Is routine digital rectal examination required for the followup of prostate cancer?
    J Urol, 178(1): 115-9. [Abstract] [Full-text]
  40. Does the intrarectal instillation of lidocaine gel before periprostatic neurovascular bundle block during transrectal ultrasound guided prostate biopsies improve analgesic efficacy? A prospective, randomized trial.
    J Urol, 178(1): 103-6. [Abstract] [Full-text]
  41. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
    J Urol, 178(1): 111-4. [Abstract] [Full-text]
  42. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
    J Urol, 178(1): 93-7; discussion 97. [Abstract] [Full-text]
  43. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    J Urol, 178(1): 107-9; discussion 110. [Abstract] [Full-text]
  44. Clinical judgment analysis of the parameters used by consultant urologists in the management of prostate cancer.
    J Urol, 178(1): 98-102. [Abstract] [Full-text]
  45. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer.
    J Clin Oncol, 25(18): 2560-6. [Abstract] [Full-text]
  46. Prostate-specific antigen in the early detection of prostate cancer.
    CMAJ, 176(13): 1853-8. [Abstract] [Full-text]
  47. Umbilical metastasis from prostate carcinoma (Sister Mary Joseph's nodule): a case report and review of literature.
    J Cutan Pathol, 34(7): 581-3. [Abstract] [Full-text]
  48. Prostate cancer progression and survival in BRCA2 mutation carriers.
    J Natl Cancer Inst, 99(12): 929-35. [Abstract] [Full-text]
  49. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
    Anticancer Drugs, 18(7): 809-16. [Abstract] [Full-text]
  50. Psychometric properties of a prostate cancer radiation late toxicity questionnaire.
    Health Qual Life Outcomes, 5: 29. [Abstract] [Full-text]
  51. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Mol Pharmacol, 72(1): 73-85. [Abstract] [Full-text]
  52. Synchronous male breast cancer and carcinoma of prostate in 90-year-old male, presented with spinal cord compression and multiple spine lytic lesions.
    Breast J, 13(4): 410-2. [Abstract] [Full-text]
  53. The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age.
    Prostate, 67(11): 1247-54. [Abstract] [Full-text]
  54. Androgens and prostate cancer risk: a prospective study.
    Prostate, 67(11): 1230-7. [Abstract] [Full-text]
  55. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Prostate, 67(11): 1219-29. [Abstract] [Full-text]
  56. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis.
    Prostate, 67(11): 1202-10. [Abstract] [Full-text]
  57. Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells.
    Prostate, 67(11): 1211-8. [Abstract] [Full-text]
  58. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Prostate, 67(11): 1182-93. [Abstract] [Full-text]
  59. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Prostate, 67(11): 1194-201. [Abstract] [Full-text]
  60. A population study of neutering status as a risk factor for canine prostate cancer.
    Prostate, 67(11): 1174-81. [Abstract] [Full-text]
  61. Exploration of target molecules for prostate cancer gene therapy.
    Prostate, 67(11): 1163-73. [Abstract] [Full-text]
  62. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
    Prostate, 67(11): 1143-51. [Abstract] [Full-text]
  63. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Prostate, 67(11): 1152-62. [Abstract] [Full-text]
  64. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
    J Clin Pathol, 60(7): 773-80. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

American Cancer Society's Complete Guide to Prostate Cancer

American Cancer Society's Complete Guide to Prostate Cancer